TY - JOUR AU - Gregor Verhoef, AU - Tadeusz Robak, AU - Huiqiang Huang, AU - Halyna Pylypenko, AU - Noppadol Siritanaratkul, AU - Juliana Pereira, AU - Johannes Drach, AU - Jiri Mayer, AU - Rumiko Okamoto, AU - Lixia Pei, AU - Brendan Rooney, AU - Andrew Cakana, AU - Helgi van de Velde, AU - Franco Cavalli, PY - 2017/04/30 Y2 - 2024/03/29 TI - Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study JF - Haematologica JA - haematol VL - 102 IS - 5 SE - Articles DO - 10.3324/haematol.2016.152496 UR - https://haematologica.org/article/view/8069 SP - 895-902 AB - In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P